Last updated: March 9, 2023
Sponsor: Collegium Medicum w Bydgoszczy
Overall Status: Active - Not Recruiting
Phase
3
Condition
Occlusions
Cardiac Disease
Chest Pain
Treatment
N/AClinical Study ID
NCT05779059
2023/01
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- provision of informed consent prior to any study specific procedures
- diagnosis of non-ST-segment elevation acute coronary syndrome (non-ST-segmentelevation myocardial treatment or unstable angina)
- male or non-pregnant female, aged 18-75 years old
Exclusion
Exclusion Criteria:
- known hypersensitivity to ticagrelor or prasugrel
- presence of contraindications for ticagrelor or prasugrel
- current treatment with oral anticoagulant or chronic therapy with low-molecular-weightheparin
- history of ischemic stroke or transient ischemic attack
- history of intracranial hemorrhage
- recent gastrointestinal bleeding (within 30 days)
- history of moderate or severe hepatic impairment
- history of major surgery or severe trauma (within 3 months)
- patient required dialysis
- concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole,voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir,nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin,carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment
- body weight below 60 kg
Study Design
Total Participants: 50
Study Start date:
April 01, 2023
Estimated Completion Date:
December 31, 2024
Connect with a study center
Department of Cardiology, Dr. A. Jurasz University Hospital, Collegium Medicum, Nicolaus Copernicus University
Bydgoszcz, Kujawsko-pomorskie 85-094
PolandSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.